CING Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.04%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Cingulate Insider Trading History Chart

Cingulate Share Price & Price History

^$3.82

▼ -0.05 (-1.29%)

As of 12/17/2025 05:00 PM ET

Days: 30 | 90 | 365

Cingulate Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/15/2024	Laurie Myers	COO	Sell	202	$4.17	$842.34
3/15/2024	Jennifer L Callahan	CFO	Buy	55	$27.10	$1,490.50	2,333
9/15/2023	Jennifer L Callahan	Insider	Buy	250	$13.40	$3,350.00	2,275
8/11/2023	Peter J Werth	Director	Buy	91,157	$11.00	$1,002,727.00	139,916
5/15/2023	Jennifer L Callahan	Insider	Buy	100	$20.20	$2,020.00	2,025
5/12/2023	Jennifer L Callahan	Insider	Buy	200	$21.60	$4,320.00	1,925
12/16/2022	Shane J Schaffer	CEO	Buy	500	$20.40	$10,200.00	2,075

SEC Filings (Institutional Ownership Changes) for Cingulate (NASDAQ:CING)

41.31% of Cingulate stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cingulate Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/10/2025	Quantum Private Wealth LLC	24,000	$94K	0.0%	+140.0%	0.444%
8/15/2025	Bank of America Corp DE	7,501	$31K	0.0%	+283.1%	0.143%
8/12/2025	XTX Topco Ltd	10,943	$45K	0.0%	N/A	0.208%
2/12/2025	Geode Capital Management LLC	27,323	$0.14M	0.0%	N/A	0.851%
2/10/2025	Commonwealth Equity Services LLC	43,022	$0.21M	0.0%	+281.5%	1.340%
1/21/2025	AlphaMark Advisors LLC	5,010	$25K	0.0%	+50,000.0%	0.156%
11/15/2024	Jane Street Group LLC	21,031	$0.11M	0.0%	N/A	0.655%
8/15/2024	Armistice Capital LLC	490,000	$0.16M	0.0%	N/A	6.671%
11/15/2023	Armistice Capital LLC	754,792	$0.54M	0.0%	N/A	4.820%
10/23/2023	Commonwealth Equity Services LLC	100,771	$71K	0.0%	N/A	0.643%
5/5/2023	Prime Capital Investment Advisors LLC	48,262	$48K	0.0%	N/A	0.413%
11/8/2022	Eagle Asset Management Inc.	107,527	$0.12M	0.0%	+124.5%	0.951%
5/12/2022	Eagle Asset Management Inc.	47,895	$94K	0.0%	N/A	0.424%
5/5/2022	Lynwood Capital Management Inc.	225,994	$0.45M	0.5%	+80.8%	1.998%
2/14/2022	Altium Capital Management LP	83,931	$0.23M	0.1%	N/A	0.742%

Data available starting January 2016

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Today's Range

Now: $3.82

$3.82

$4.10

50 Day Range

MA: $3.79

$3.33

$4.44

52 Week Range

Now: $3.82

$3.20

$6.01

Volume

101,115 shs

Average Volume

152,801 shs

Market Capitalization

$25.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cingulate?: Cingulate's top insider investors include:
Jennifer L Callahan (CFO)
Laurie Myers (COO)
Learn More about top insider investors at Cingulate.
Who are the major institutional investors of Cingulate?: Cingulate's top institutional investors include:
Quantum Private Wealth LLC — 0.44%
Learn More about top institutional investors of Cingulate stock.
Which major investors are buying Cingulate stock?: During the last quarter, CING stock was bought by institutional investors including:
Quantum Private Wealth LLC